19
Jun
2024

BrightGene Bio-Medical Technology Co., Ltd.

Exhibitor at CPHI & PMEC China 2024 stand W2B01, Pharma Ingredients
About Us

BrightGene Bio-medical Technology Co Ltd is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market. 

We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis....

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2015
    On CPHI since
View company profile
Contact info
  • +86 512-62551764
  • Website
  • Room C26-C27, Suzhou biological nano-technology park, No.218 Xinghu Street, 215123, Suzhou, China
Show contact info Hide contact info
Event information
CPHI & PMEC China 2024
  • 19 - 21 June 2024
  • Shanghai New International Expo Center
  • Visit us at stand W2B01, Pharma Ingredients

Products Featured at CPHI & PMEC China 2024

  • MMAF

    Product MMAF

    • Status: Pre-validation • Usage:  Antibody-drug Conjugate
  • MMAE

    Product MMAE

    • Status: Pre-validation • Usage:  Antibody-drug Conjugate
  • Maytansinol

    Product Maytansinol

    • Status: Pre-validation • Usage:  Antibody-drug Conjugate
  • DM-4

    Product DM-4

    • Status: Pre-validation • Usage:  Antibody-drug Conjugate
  • DM-1

    Product DM-1

    • Status: Validated • Usage:  Antibody-drug Conjugate